Is Edwards Lifesciences Corp (EW) overvalued? · P/E 47, rev $1.39B
Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE.
This page asks whether Edwards Lifesciences Corp (EW) looks expensive on cached numbers — not a short thesis.
Latest reported EW revenue for 2024-12-31 was $1.39B. Net income was $385.6M. Revenue was up 2.3% from 2024-09-30 to 2024-12-31. EW currently screens at market cap $49.91B and trailing P/E 46.9.
EW currently screens at market cap $49.91B and trailing P/E 46.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next EW 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the EW stock page for the full model, not this heading.
Not investment advice.